Fatigue, a Confirmed Deficiency, and a Benefit Nobody Can Fully Prove
A single patient, biochemically confirmed adult growth hormone deficiency after pituitary surgery, weighing whether to start replacement. The disagreement isn't about the diagnosis — it's about how much weight to put on a benefit the literature itself hasn't fully settled.
C.W., a 47-year-old man, ran his own drywall crew for two decades before a nonfunctioning macroadenoma, resected fourteen months ago, left him with confirmed panhypopituitarism now fully replaced on hydrocortisone, levothyroxine, and testosterone. What brought him back for this specific conversation is a fatigue that hasn't lifted the way the rest of his labs have normalized — he describes finishing a workday and having nothing left for the evening, a change from a man who used to coach his son's baseball team three nights a week and simply doesn't anymore. An insulin tolerance test, performed six months after his other axes were stabilized and repeated once to confirm, showed a peak GH response of 1.8 ng/mL, well below the diagnostic cutoff and consistent with severe adult GH deficiency layered on top of his other confirmed deficiencies rather than a false-low result from inadequately treated hypocortisolism or hypothyroidism, both of which were corrected before testing.
The evidence for treating him is real but genuinely more contested than the other three replacements he's already on. Randomized trials of GH replacement in adult GHD consistently show improvements in body composition — lean mass up, fat mass down — bone mineral density, and lipid profile, and large observational registries built from thousands of treated patients report meaningful quality-of-life gains that track closely with his own complaint. What the literature has not clearly established, because the trials are short relative to a lifelong therapy and use surrogate endpoints rather than hard outcomes, is a proven reduction in cardiovascular events or mortality from replacement itself — the case for starting GH rests on quality of life and metabolic markers a clinician can measure, not on outcomes a clinician can promise, a genuinely different evidentiary footing than his hydrocortisone or thyroid replacement, where undertreatment has clear, acute, measurable consequences.
A real diagnosis, a real drug, and a benefit that's genuinely hard to pin down
I'd start GH replacement. His deficiency is confirmed twice, severe, and his symptom picture — fatigue, reduced function, mild dyslipidemia, early bone loss — is exactly the cluster the replacement trials and the large observational registries consistently show improving. He's not an ambiguous case biochemically; the ambiguity is only in how the benefit gets measured, not whether it exists.
I'd want to name that measurement gap directly before starting, not treat it as a footnote. The registry data is real, but it's largely observational and industry-supported, and the randomized trials that exist are built around surrogate endpoints — lean mass, LDL, bone density — not hard outcomes like cardiovascular events or mortality, which simply haven't been shown to improve with adult GH replacement over any trial duration run so far.
That's a genuinely different evidentiary position than the rest of his regimen. Nobody debates hydrocortisone in a hypocortisolic patient because the alternative is measurable, acute harm; here the alternative to treating is a real but harder-to-quantify quality-of-life cost, and I don't think that distinction should get flattened into "he's deficient, therefore treat," the same reasoning that applies cleanly to his other three hormones.
That's a fair distinction and I'd rather make the case on his own terms than lean on the registries alone. His actual complaint — fatigue specific enough to have changed what he does with his evenings — is the outcome the randomized quality-of-life data was built to capture, not an assumption; and his DEXA and lipid findings give us objective markers to follow rather than relying on symptom report alone. I'd frame this as a trial with defined stopping criteria if he doesn't improve, not a lifelong commitment made on faith.
Agreed: start somatropin as an explicit trial, titrated by IGF-1, with a 12-month reassessment built around his own presenting symptom (evening fatigue and functional capacity) plus the objective markers — lipids and DEXA — the trial evidence actually measures, rather than starting therapy on the strength of the diagnosis alone or declining it on the strength of the evidentiary gap alone.
Not resolved, and named as such rather than smoothed over: whether adult GH replacement's quality-of-life benefit, real as it appears in symptomatic patients like him, justifies its cost and daily-injection burden as a lifelong therapy given the absence of proven hard-outcome benefit. Both physicians agreed on the trial as designed; neither claimed the underlying evidentiary question was settled by agreeing to run it.